Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

UK Radioligand Therapy Market

ID: MRFR/Pharma/50329-HCR
200 Pages
Rahul Gotadki
Last Updated: March 28, 2026

UK Radioligand Therapy RLT Market Research Report By Isotope (Fluorine – 18, Gallium – 68, Lutetium – 177, Others), By Targeted Receptor (Prostate-specific Membrane Antigen (PSMA), Somatostatin Receptor (SSTR), Epidermal Growth Factor Receptor (EGFR), Others), By Indication (Prostate Cancer, Neuroendocrine Tumors (NETs), Breast Cancer, Others) and By End User (Hospitals & Clinics, Diagnostic Centers, Others) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

UK Radioligand Therapy Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Application (USD Billion)
  49.     4.1.1 Oncology
  50.     4.1.2 Cardiology
  51.     4.1.3 Neurology
  52.     4.1.4 Endocrinology
  53.   4.2 Healthcare, BY End Use (USD Billion)
  54.     4.2.1 Hospitals
  55.     4.2.2 Diagnostic Centers
  56.     4.2.3 Research Institutions
  57.   4.3 Healthcare, BY Type of Radioligand (USD Billion)
  58.     4.3.1 Alpha Emitters
  59.     4.3.2 Beta Emitters
  60.     4.3.3 Auger Electron Emitters
  61.   4.4 Healthcare, BY Administration Route (USD Billion)
  62.     4.4.1 Intravenous
  63.     4.4.2 Oral
  64.     4.4.3 Subcutaneous
  65.   4.5 Healthcare, BY Target Disease (USD Billion)
  66.     4.5.1 Prostate Cancer
  67.     4.5.2 Neuroendocrine Tumors
  68.     4.5.3 Lymphoma
  69. 5 SECTION V: COMPETITIVE ANALYSIS
  70.   5.1 Competitive Landscape
  71.     5.1.1 Overview
  72.     5.1.2 Competitive Analysis
  73.     5.1.3 Market share Analysis
  74.     5.1.4 Major Growth Strategy in the Healthcare
  75.     5.1.5 Competitive Benchmarking
  76.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  77.     5.1.7 Key developments and growth strategies
  78.       5.1.7.1 New Product Launch/Service Deployment
  79.       5.1.7.2 Merger & Acquisitions
  80.       5.1.7.3 Joint Ventures
  81.     5.1.8 Major Players Financial Matrix
  82.       5.1.8.1 Sales and Operating Income
  83.       5.1.8.2 Major Players R&D Expenditure. 2023
  84.   5.2 Company Profiles
  85.     5.2.1 Novartis (GB)
  86.       5.2.1.1 Financial Overview
  87.       5.2.1.2 Products Offered
  88.       5.2.1.3 Key Developments
  89.       5.2.1.4 SWOT Analysis
  90.       5.2.1.5 Key Strategies
  91.     5.2.2 Bayer (GB)
  92.       5.2.2.1 Financial Overview
  93.       5.2.2.2 Products Offered
  94.       5.2.2.3 Key Developments
  95.       5.2.2.4 SWOT Analysis
  96.       5.2.2.5 Key Strategies
  97.     5.2.3 AstraZeneca (GB)
  98.       5.2.3.1 Financial Overview
  99.       5.2.3.2 Products Offered
  100.       5.2.3.3 Key Developments
  101.       5.2.3.4 SWOT Analysis
  102.       5.2.3.5 Key Strategies
  103.     5.2.4 Bristol-Myers Squibb (GB)
  104.       5.2.4.1 Financial Overview
  105.       5.2.4.2 Products Offered
  106.       5.2.4.3 Key Developments
  107.       5.2.4.4 SWOT Analysis
  108.       5.2.4.5 Key Strategies
  109.     5.2.5 Eli Lilly (GB)
  110.       5.2.5.1 Financial Overview
  111.       5.2.5.2 Products Offered
  112.       5.2.5.3 Key Developments
  113.       5.2.5.4 SWOT Analysis
  114.       5.2.5.5 Key Strategies
  115.     5.2.6 Siemens Healthineers (GB)
  116.       5.2.6.1 Financial Overview
  117.       5.2.6.2 Products Offered
  118.       5.2.6.3 Key Developments
  119.       5.2.6.4 SWOT Analysis
  120.       5.2.6.5 Key Strategies
  121.     5.2.7 GE Healthcare (GB)
  122.       5.2.7.1 Financial Overview
  123.       5.2.7.2 Products Offered
  124.       5.2.7.3 Key Developments
  125.       5.2.7.4 SWOT Analysis
  126.       5.2.7.5 Key Strategies
  127.     5.2.8 Ipsen (GB)
  128.       5.2.8.1 Financial Overview
  129.       5.2.8.2 Products Offered
  130.       5.2.8.3 Key Developments
  131.       5.2.8.4 SWOT Analysis
  132.       5.2.8.5 Key Strategies
  133.     5.2.9 Lantheus Medical Imaging (GB)
  134.       5.2.9.1 Financial Overview
  135.       5.2.9.2 Products Offered
  136.       5.2.9.3 Key Developments
  137.       5.2.9.4 SWOT Analysis
  138.       5.2.9.5 Key Strategies
  139.   5.3 Appendix
  140.     5.3.1 References
  141.     5.3.2 Related Reports
  142. 6 LIST OF FIGURES
  143.   6.1 MARKET SYNOPSIS
  144.   6.2 UK MARKET ANALYSIS BY APPLICATION
  145.   6.3 UK MARKET ANALYSIS BY END USE
  146.   6.4 UK MARKET ANALYSIS BY TYPE OF RADIOLIGAND
  147.   6.5 UK MARKET ANALYSIS BY ADMINISTRATION ROUTE
  148.   6.6 UK MARKET ANALYSIS BY TARGET DISEASE
  149.   6.7 KEY BUYING CRITERIA OF HEALTHCARE
  150.   6.8 RESEARCH PROCESS OF MRFR
  151.   6.9 DRO ANALYSIS OF HEALTHCARE
  152.   6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  153.   6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  154.   6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
  155.   6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
  156.   6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
  157.   6.15 HEALTHCARE, BY END USE, 2024 (% SHARE)
  158.   6.16 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion)
  159.   6.17 HEALTHCARE, BY TYPE OF RADIOLIGAND, 2024 (% SHARE)
  160.   6.18 HEALTHCARE, BY TYPE OF RADIOLIGAND, 2024 TO 2035 (USD Billion)
  161.   6.19 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
  162.   6.20 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion)
  163.   6.21 HEALTHCARE, BY TARGET DISEASE, 2024 (% SHARE)
  164.   6.22 HEALTHCARE, BY TARGET DISEASE, 2024 TO 2035 (USD Billion)
  165.   6.23 BENCHMARKING OF MAJOR COMPETITORS
  166. 7 LIST OF TABLES
  167.   7.1 LIST OF ASSUMPTIONS
  168.     7.1.1
  169.   7.2 UK MARKET SIZE ESTIMATES; FORECAST
  170.     7.2.1 BY APPLICATION, 2026-2035 (USD Billion)
  171.     7.2.2 BY END USE, 2026-2035 (USD Billion)
  172.     7.2.3 BY TYPE OF RADIOLIGAND, 2026-2035 (USD Billion)
  173.     7.2.4 BY ADMINISTRATION ROUTE, 2026-2035 (USD Billion)
  174.     7.2.5 BY TARGET DISEASE, 2026-2035 (USD Billion)
  175.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  176.     7.3.1
  177.   7.4 ACQUISITION/PARTNERSHIP
  178.     7.4.1

UK Healthcare Market Segmentation

Healthcare By Application (USD Billion, 2026-2035)

  • Oncology
  • Cardiology
  • Neurology
  • Endocrinology

Healthcare By End Use (USD Billion, 2026-2035)

  • Hospitals
  • Diagnostic Centers
  • Research Institutions

Healthcare By Type of Radioligand (USD Billion, 2026-2035)

  • Alpha Emitters
  • Beta Emitters
  • Auger Electron Emitters

Healthcare By Administration Route (USD Billion, 2026-2035)

  • Intravenous
  • Oral
  • Subcutaneous

Healthcare By Target Disease (USD Billion, 2026-2035)

  • Prostate Cancer
  • Neuroendocrine Tumors
  • Lymphoma

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓